Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

130.01 +2.01 (+1.57%)
Streaming Delayed Price Updated: 11:13 AM EDT, Jul 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Neurocrine Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
3 Biotech Stocks to Watch: Iovance, Neurocrine & Viking
Timing matters with biotech stocks; these three companies offer distinct risk-reward profiles but have upcoming catalysts that could redefine their value 
Via MarketBeat
Topics Artificial Intelligence Economy
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Promising Affordable Growth Stock
NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it an attractive candidate for investors seeking affordable growth in the biotech sector. 
Via Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potential
NEUROCRINE BIOSCIENCES (NBIX) shows strong growth, profitability, and a bullish technical setup, making it a stock worth watching for growth investors. 
Via Chartmill
Analyst Expectations For Neurocrine Biosciences's Future
Via Benzinga
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) - A Strong Growth Stock with Reasonable Valuation
NEUROCRINE BIOSCIENCES (NBIX) offers strong growth, solid profitability, and reasonable valuation, making it a candidate for investors seeking affordable growth stocks in the biotech sector. 
Via Chartmill
Earnings Scheduled For May 5, 2025
Via Benzinga
Assessing Neurocrine Biosciences: Insights From 15 Financial Analysts
Via Benzinga
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) – A Strong Growth Stock with Technical Breakout Potential
NEUROCRINE BIOSCIENCES (NBIX) shows strong growth fundamentals and a promising technical setup, making it a stock to watch for potential breakout opportunities. 
Via Chartmill
Neurocrine Biosciences' Ingrezza Q1 Sales Prove Resilient, Analysts Boost Price Target
Neurocrine stock gains as Q1 EPS beats estimates; Ingrezza sales climb 8% YoY with record new patients and strong analyst price target hikes. 
Via Benzinga
Neurocrine Biosciences Surges On 'Surprising' Momentum For Its Newest Drug
The company reported a strong start for its newest drug, Crenessity, which treats a hormonal disorder involving the adrenal glands. 
Via Investor's Business Daily
FARO Technologies, Celanese, Avient, Aramark And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
What 19 Analyst Ratings Have To Say About Neurocrine Biosciences
Via Benzinga
Neurocrine Biosciences Stock Surges After-Hours On Upbeat Q1, Reaffirmed Ingrezza Outlook — Retail Buzz Soars
CEO Kyle Gano highlighted record new patient starts for Ingrezza and noted positive early response to the launch of Crenessity, positioning the company for sustained growth. 
Via Stocktwits
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Top movers in Monday's after hours session
As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses. 
Via Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is not too expensive for the growth it is showing.
Discover NEUROCRINE BIOSCIENCES INC, an undervalued growth gem. NASDAQ:NBIX is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an... 
Via Chartmill
What to Expect from Neurocrine Biosciences's Earnings
Via Benzinga
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Strong Affordable Growth Stock
Neurocrine Biosciences Inc (NASDAQ:NBIX): A Strong Affordable Growth Stock 
Via Chartmill
In The Holiday Shortened Easter Week, These Large-Cap Stock Were Top Performers (Apr 14-Apr 18): Are These In Your Portfolio?
Top performers last week: ServiceTitan, Summit Therapeutics, YPF, Eli Lilly, MicroStrategy, America Movil, Ericsson, Insmed, Diamondback, Neurocrine Biosciences. 
Via Benzinga
Neurocrine Biosciences' Positive Crenessity Physician Survey Turns This Analyst Bullish
Physician survey shows high uptake of Neurocrine Biosciences' Crenessity for patients with CAH. 
Via Benzinga
What 16 Analyst Ratings Have To Say About Neurocrine Biosciences
Via Benzinga
This Triumph Group Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday
Via Benzinga
Looking for growth without the hefty price tag? Consider NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX).
Based on Fundamental Analysis it can be said that NASDAQ:NBIX is a growth stock which is not overvalued. 
Via Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is an undervalued gem with solid fundamentals.
Discover NEUROCRINE BIOSCIENCES INC, an undervalued stock. NASDAQ:NBIX showcases solid financial health and profitability while maintaining an appealing valuation. 
Via Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—A High-Growth Stock Gearing Up for Its Next Upward Move.
Based on a technical and fundamental analysis of NASDAQ:NBIX we can say: NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX)—Positioned as a High-Growth Stock, Ready for a Potential Breakout. 
Via Chartmill
Neurocrine Biosciences: A Smart Biotech Bet With Blockbuster Potential
Via The Motley Fool
Deep Dive Into Neurocrine Biosciences Stock: Analyst Perspectives (14 Ratings)
Via Benzinga
Despite its growth, NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) remains within the realm of affordability.
NASDAQ:NBIX is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
NEUROCRINE BIOSCIENCES INC has a stellar value proposition. NASDAQ:NBIX not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point. 
Via Chartmill
NASDAQ:NBIX is showing decent growth, but is still valued reasonably.
NASDAQ:NBIX is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced. 
Via Chartmill
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.